Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: Lessons learned

Journal of Gastrointestinal Surgery

Volumn 11, Issue 3, 2007, Pages 264-271

  Bloomston, Mark ^a,b   Al Saif, Osama ^a   Klemanski, Dori ^a   Pinzone, Joseph J ^a   Martin, Edward W ^a   Palmer, Bryan ^a   Guy, Gregory ^a   Khabiri, Hooman ^a   Ellison, E Christopher ^a   Shah, Manisha H ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Carcinoid; Chemoembolization; HACE; Metastatic; Pancreastatin

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOID; CHEMOEMBOLIZATION; FEMALE; HEPATIC ARTERY; HUMAN; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; SURVIVAL RATE;

EID: 34247554921     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0089-z     Document Type: Article

References (29)

1. Modlin IM, Lye KD, Kidd M, A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934-959.
2. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79(4):813-829.
3. Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vase Interv Radiol 1999;10(4):397-403.
4. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Weltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995;169(5):523-528.
5. Drougas JO, Anthony LB, Blair TK, Lopez RR, Wright JK, Jr., Chapman WC, Webb L, Mazer M, Meranze S, Pinson CW. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998;175(5):408-412.
6. Nobin A, Mansson B, Lunderquist A. Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumour. Acta Oncol 1989;28(3):419-424.
7. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19(4):585-594.
8. Atwell TD, Charboneau JW, Que FG, Rubin J, Lewis BD, Nagorney DM, Callstrom MR, Farrell MA, Pilot HC, Hobday TJ. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Interv Radiol 2005;28(4):409-421.
9. Desai DC, O'Dorisio TM, Schirmer WJ, Jung SS, Khabiri H, Villanueva V, Martin EW. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept 2001;96(3):113-117.
10. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006;13(1):72-78.
11. Gupto S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104(8):1590-1602.
12. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432-445.
13. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006;13(4):572-581.
14. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12(1):231-242.
15. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, Ott MJ. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229(6):815-821; discussion 822-823.
16. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S, Joehl RJ. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130(4):677-682; discussion 682-685.
17. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003;9(4):261-267.
18. Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005;241(6):839-845; discussion 845-6.
19. Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 1995;60(2):116-121.
20. Ramage JK, Davies AH. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer 2003;10(4):483-486.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
22. Calhoun K, Toth-Fejel S, Cheek J, Pommier R. Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003;186(1):28-31.
23. Kimura N, Funakoshi A, Aunis D, Tateishi K, Miura W, Nagura H. Immunohistochemical localization of chromostatin and pancreastatin, chromogranin A-derived bioactive peptides, in normal and neoplastic neuroendocrine tissues. Endocr Pathol 1995;6(1):35-43.
24. Oberg K. The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. Digestion 1996;57 Suppl 1:45-47.
25. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995;144(1):49-59.
26. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83(11):2293-2301.
27. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71(8):2624-2630.
28. Kim YH, Ajani JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999;17(7):474-478.
29. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116(6):1111-1116; discussion 1116-1117.